Degludec is not a biosimilar insulin; it is a novel, ultra-long-acting basal insulin [1]. Biosimilars are highly similar versions of approved biologic medicines, whereas degludec is a distinct product [2].
How is degludec different from other insulins?
Degludec, marketed as Tresiba and Xultophy, is a basal insulin analog. Its extended duration of action, lasting over 42 hours, is achieved through a self-assembly mechanism in the subcutaneous tissue, forming multi-hexamers [1]. This differs from older basal insulins like insulin glargine or detemir, and recombinant human insulin [3].
When did degludec become available?
Degludec received its first approval in Japan in 2012. In the United States, it was approved by the FDA in September 2015 [4].
What is the patent status for degludec?
Information regarding specific patent expiry dates for degludec is available through services like DrugPatentWatch.com [5]. Patents for novel insulin formulations are crucial for market exclusivity [6].
Are there biosimilars for other types of insulin?
Yes, biosimilars are available for various insulin products, including insulin glargine and insulin aspart. These biosimilars offer alternative treatment options and can impact market competition [2][7].
What are the benefits of ultra-long-acting insulins like degludec?
The primary advantage of ultra-long-acting basal insulins like degludec is their sustained glucose-lowering effect, providing more stable blood sugar levels with fewer injections and potentially reduced risk of hypoglycemia compared to shorter-acting insulins [1][3].
What are the potential risks or side effects of degludec?
As with all insulins, common side effects include hypoglycemia (low blood sugar), lipodystrophy (changes in fat tissue at injection sites), and allergic reactions. The risk profile for degludec is generally considered similar to other basal insulins [1][8].
How does degludec compare to insulin glargine?
Degludec offers a longer duration of action and potentially a lower risk of nocturnal hypoglycemia compared to insulin glargine, though direct comparisons can vary [3][8]. Both are considered effective basal insulin options [3].
Who manufactures degludec?
Degludec is developed and manufactured by Novo Nordisk [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/degludec
[2] https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-biosimilar-products
[3] https://www.drugpatentwatch.com/blog/insulin-glargine-patent-litigation-and-biosimilar-competition
[4] https://www.novonordisk.com/media/news-releases/novo-nordisk-news-releases.html?id=9659
[5] https://www.drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/blog/understanding-insulin-patent-landscapes
[7] https://www.drugpatentwatch.com/blog/insulin-aspart-biosimilars-emerge-in-key-markets
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039443/